Literature DB >> 12701855

The acceptability of different routes of administration of analgesia for breakthrough pain.

G Walker1, A Wilcock, C Manderson, R Weller, V Crosby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12701855     DOI： 10.1191/0269216303pm755oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN： 0269-2163            Impact factor:   4.762


× No keyword cloud information.
  10 in total

1.  Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.

Authors:  Lukas Radbruch; Luis M Torres; John E Ellershaw; Antonio Gatti; Guillermo Luis Lerzo; Julia Revnic; Donald Taylor
Journal:  Support Care Cancer       Date:  2011-03-22       Impact factor: 3.603

2.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

3.  Carer preferences of route of administration of transmucosal diamorphine and willingness to take part in a randomised controlled trial: an interview study (DIPPER).

Authors:  Liz Jamieson; Emily Harrop; Christina Liossi; Katherine Boyce; Lorraine Mitchell; Margaret Johnson; Yogini Jani; Victoria Akinyooye; Simon S Skene; Ian C K Wong; Richard F Howard; Kate Oulton
Journal:  BMC Palliat Care       Date:  2022-05-17       Impact factor: 3.113

4.  Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany.

Authors:  Steffen T Simon; Anna Maria Niemand; Hamid Benalia; Raymond Voltz; Irene J Higginson; Claudia Bausewein
Journal:  J Palliat Med       Date:  2012-10-24       Impact factor: 2.947

Review 5.  A comprehensive review of rapid-onset opioids for breakthrough pain.

Authors:  Howard Smith
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

6.  Single-dose fentanyl sublingual spray for breakthrough cancer pain.

Authors:  Donald R Taylor
Journal:  Clin Pharmacol       Date:  2013-07-24

7.  Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.

Authors:  Paolo Angelo Cortesi; Lucia Sara D'Angiolella; Renato Vellucci; Massimo Allegri; Giuseppe Casale; Carlo Favaretti; Flavia Kheiraoui; Giancarlo Cesana; Lorenzo Giovanni Mantovani
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

Review 8.  Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.

Authors:  Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong
Journal:  Adv Drug Deliv Rev       Date:  2020-11-01       Impact factor: 15.470

Review 9.  Challenges with Assessing and Treating Pain in Research Primates: A Focused Survey and Literature Review.

Authors:  Emilie A Paterson; Patricia V Turner
Journal:  Animals (Basel)       Date:  2022-09-05       Impact factor: 3.231

10.  Considerations in selecting rapid-onset opioids for the management of breakthrough pain.

Authors:  Howard S Smith
Journal:  J Pain Res       Date:  2013-03-06       Impact factor: 3.133
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.